Intellia Therapeutics Secures $70 Million in Series B Financing
Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology Pipeline Primarily Focused on Disorders of the Liver and Blood CAMBRIDGE, Mass., Sept. 1, 2015 – Intellia Therapeutics, a leading gene-editing company focused on the development of
In May, both the National Institutes of Health (NIH) and the White House voiced concern over ethical issues associated with using gene-editing technology to alter the human germline. The White House Office of Scientific Assessment further stated that, "the Administration believes that altering the
Intellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance and Strategy Officer
CAMBRIDGE, Mass., April 22, 2015 —Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, announced today the appointment of Dr. Sapna Srivastava as Chief Financial and Strategy Officer.
Intellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company
CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 for gene editing and repair, announced today that Jennifer Doudna, PhD, and Derrick Rossi, PhD, will join Intellia as founding members and scientific advisors of the Company. Dr.
Intellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology
Five-Year Collaboration Focused on CART and Hematopoetic Stem Cell Applications across a Range of Therapeutic Areas CAMBRIDGE, Mass.—January 7, 2015—Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment